Long-term follow-up for people who received azer-cel
This study checks how people do over a longer period after receiving azer-cel in an Imugene trial. It helps doctors understand long-term safety and health outcomes, even if you are feeling well now.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You received at least one dose of azer-cel in an Imugene clinical study
- You can sign a study consent form (informed consent)
- You are willing and able to follow the study’s visit schedule and instructions
- There are no special exclusion rules listed for this follow-up
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study follows people who have already received a CRISPR CAR T cell therapy to monitor their long-term health and any side effects. It helps doctors understand how these treatments work over time.
This study is for people who already received the experimental treatment azer-cel in a previous trial. It will follow you over the long term to see how you're doing and monitor any lasting effects.
This trial tests an investigational cell therapy called Azer-cel for people with certain types of blood cancer (non-Hodgkin lymphoma, chronic lymphocytic leukemia/small lymphocytic lymphoma, or B-cell acute lymphoblastic leukemia) that has come back or not responded to previous treatments. The therapy uses your own immune cells that have been modified to find and attack cancer cells.
This study is a long-term follow-up for people who have already received a cell or gene therapy in a previous AstraZeneca trial. It helps researchers monitor your health over time to make sure the therapy is safe and effective.
This study follows patients who have had gene-modified T-cell therapy to track their health over time. It does not test a new treatment but helps doctors understand long-term effects.
This study tracks people who received a specific CAR-T cell therapy made by AvenCell. The goal is to monitor their health over time to better understand long-term effects.
Hear when a new Participants Who Received an Allogeneic Chimeric Antigen Receptor T-Cell Product (PBCAR) in a Precision BioSciences, Inc., Clinical Study trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.